<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03082079</url>
  </required_header>
  <id_info>
    <org_study_id>LC2016YM002</org_study_id>
    <nct_id>NCT03082079</nct_id>
  </id_info>
  <brief_title>Long Outcome of Endoscopic Submucosal Dissection for Small Gastrointestinal Stromal Tumors (&lt;2cm)</brief_title>
  <official_title>Long Outcome of Endoscopic Submucosal Dissection for Small Gastrointestinal Stromal Tumors (&lt;2cm) :a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Data are currently insufficient to guide the management of very small gastrointestinal
      stromal tumors（GISTs）（&lt; 2 cm) discovered incidentally on endoscopy,this study is designed to
      collect the medical records of patients in different treatment group with long-term follow-up
      data,and attempts to evaluate the usefulness of regular endoscopic
      ultrasound（EUS）surveillance and the necessity,safety and feasibility of endoscopic submucosal
      dissection（ESD）for small GISTs,thus provide evidence for the revision of the guideline.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTION:to evaluate the usefulness of regular endoscopic ultrasound（EUS） surveillance and
      the necessity,safety and feasibility of endoscopic submucosal dissection（ESD） for small
      GISTs(&lt;2cm),thus providing evidences for the revision of the guideline.

      OUTLINE:This is a randomized controlled trial. Eligible patients are divided into 2 group
      with 45 in each.The experimental group undergo ESD for GISTs,while the investigators do no
      treatment to the control group.Then,the 2 groups will be follow up for 5 years.All data are
      analysed with the Statistical Product and Service Solutions（SPSS）statistical software.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2017</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>It is the time that passes from a patient is enrolled in this clinical trial to the date on which disease &quot;progresses&quot; or the date on which the patient dies, from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>tumor recurrence rate</measure>
    <time_frame>5 years</time_frame>
    <description>The proportion of the total number of patients with recurrence of each grop, which confirmed by endoscopic and other imaging data during follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>success rate of operations</measure>
    <time_frame>At surgery</time_frame>
    <description>The proportion of the total number of patients with GISTs been successfully resected of each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor progression rates</measure>
    <time_frame>5 years</time_frame>
    <description>The proportion of the total number of patients with tumor continuing to increase of each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operation time</measure>
    <time_frame>At surgery</time_frame>
    <description>It is the time that passes from ESD beginning to complete resection of the tumors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peri-operative bleeding</measure>
    <time_frame>At surgery</time_frame>
    <description>The amount of bleeding during operation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications rate</measure>
    <time_frame>At surgery</time_frame>
    <description>Complications including bleeding and perforation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization and the total hospital costs</measure>
    <time_frame>through the whole recovery, an average of 10 days</time_frame>
    <description>length of hospital stay and all costs related to the operations and examinations and the period of hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological curative resection</measure>
    <time_frame>At surgery</time_frame>
    <description>Histological curative resection is defined as complete tumor removal which confirmed by pathological assessment of resected tissue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient satisfaction scores</measure>
    <time_frame>5 years</time_frame>
    <description>We administer questionnaires to each patients,and invite them to score for this treatment or examination.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>GIST</condition>
  <arm_group>
    <arm_group_label>ESD group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient in this group undergo ESD for GIST, and regular follow-up are carried out for these patients on 72 ±3h,7±2d,14±2d,3 month,6 month,1 year,2 year,3 year,4 year,5 year after the treatment. The investigators record the success rate of operation,en bloc resection,operation time,complication rate,hospitalization days,hospitalization expenses,pathology results and tumor recurrence rate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Follow-up group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patient in this group are given no intervention,the investigators record the tumor size and EUS features of the first endoscopic examination.Regular follow-up are carried out for these patients on 3 month,6 month,1 year,2 year,3 year,4 year,5 year after this check.Then,tumor size and EUS features of each time are collected accurately.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ESD</intervention_name>
    <description>Patient in ESD group undergo ESD for GIST, and regular follow-up are carried out for these patients on 72 ±3h,7±2d,14±2d,3 month,6 month,1 year,2 year,3 year,4 year,5 year after the treatment. The investigators record the success rate of operation,en bloc resection,operation time,complication rate,hospitalization days,hospitalization expenses,pathology results and tumor recurrence rate</description>
    <arm_group_label>ESD group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female chinese patients of 18-70 years old.

          2. Patients with very small gastric GISTs (&lt; 2 cm) with no high-risk EUS features.

          3. Patients voluntarily join this study with informed consents.

        Exclusion Criteria:

          1. Patients with the tumors involving the serosa layer or grow outside the lumen
             obviously that are not eligible for endoscopic treatment.

          2. Patients with distant metastasis on computed tomography(CT)scan.

          3. patients with an extremely poor general condition or a very short life expectancy.

          4. Patients presenting with severe gastrointestinal tract bleeding that require immediate
             surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>yue li, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Nanfang Hospital of Southern Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>yue li, Doctor</last_name>
    <phone>15975537291</phone>
    <email>liyue_1989919@126.com</email>
  </overall_contact>
  <reference>
    <citation>Davila RE, Faigel DO. GI stromal tumors. Gastrointest Endosc. 2003 Jul;58(1):80-8. Review.</citation>
    <PMID>12838226</PMID>
  </reference>
  <reference>
    <citation>Siow SL, Mahendran HA, Wong CM. Laparoscopic transgastric resection for intraluminal gastric gastrointestinal stromal tumors located at the posterior wall and near the gastroesophageal junction. Asian J Surg. 2017 Sep;40(5):407-414. doi: 10.1016/j.asjsur.2015.12.001. Epub 2016 Feb 24.</citation>
    <PMID>26922628</PMID>
  </reference>
  <reference>
    <citation>Reichardt P. [Soft tissue sarcomas and gastrointestinal stromal tumors]. Internist (Berl). 2016 Mar;57(3):245-56. doi: 10.1007/s00108-016-0021-2. German.</citation>
    <PMID>26907871</PMID>
  </reference>
  <reference>
    <citation>Uçar AD, Oymaci E, Carti EB, Yakan S, Vardar E, Erkan N, Mehmet Y. Characteristics of Emergency Gastrointestinal Stromal Tumor (GIST). Hepatogastroenterology. 2015 May;62(139):635-40.</citation>
    <PMID>26897944</PMID>
  </reference>
  <reference>
    <citation>Sornmayura P. Gastrointestinal stromal tumors (GISTs): a pathology view point. J Med Assoc Thai. 2009 Jan;92(1):124-35. Review.</citation>
    <PMID>19260254</PMID>
  </reference>
  <reference>
    <citation>ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014 Sep;25 Suppl 3:iii21-6. doi: 10.1093/annonc/mdu255. Erratum in: Ann Oncol. 2015 Sep;26 Suppl 5:v174-7.</citation>
    <PMID>25210085</PMID>
  </reference>
  <reference>
    <citation>Maghrebi H, Chebbi F, Makni A, Haddad A, Daghfous A, Fteriche F, Rebai W, Ksantini R, Jouini M, Kacem M, Ben Safta Z. Laparoscopic resection of gastric stromal tumors. Tunis Med. 2015 Oct;93(10):594-7.</citation>
    <PMID>26895119</PMID>
  </reference>
  <reference>
    <citation>Novitsky YW, Kercher KW, Sing RF, Heniford BT. Long-term outcomes of laparoscopic resection of gastric gastrointestinal stromal tumors. Ann Surg. 2006 Jun;243(6):738-45; discussion 745-7.</citation>
    <PMID>16772777</PMID>
  </reference>
  <reference>
    <citation>Nakamori M, Iwahashi M, Nakamura M, Tabuse K, Mori K, Taniguchi K, Aoki Y, Yamaue H. Laparoscopic resection for gastrointestinal stromal tumors of the stomach. Am J Surg. 2008 Sep;196(3):425-9. doi: 10.1016/j.amjsurg.2007.10.012. Epub 2008 May 7.</citation>
    <PMID>18466871</PMID>
  </reference>
  <reference>
    <citation>Matsuhashi N, Osada S, Yamaguchi K, Okumura N, Tanaka Y, Imai H, Sasaki Y, Nonaka K, Takahashi T, Futamura M, Yoshida K. Long-term outcomes of treatment of gastric gastrointestinal stromal tumor by laparoscopic surgery: review of the literature and our experience. Hepatogastroenterology. 2013 Nov-Dec;60(128):2011-5. Review.</citation>
    <PMID>24719942</PMID>
  </reference>
  <reference>
    <citation>Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, Pisters PW, Raut CP, Riedel RF, Schuetze S, Sundar HM, Trent JC, Wayne JD. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw. 2010 Apr;8 Suppl 2:S1-41; quiz S42-4.</citation>
    <PMID>20457867</PMID>
  </reference>
  <reference>
    <citation>Deprez PH. Endoscopic diagnosis and treatment of upper gastrointestinal tumors. Endoscopy. 2011 Nov;43(11):966-70. doi: 10.1055/s-0031-1291427. Epub 2011 Nov 4. Review.</citation>
    <PMID>22057760</PMID>
  </reference>
  <reference>
    <citation>Goto O, Uraoka T, Horii J, Yahagi N. Expanding indications for ESD: submucosal disease (SMT/carcinoid tumors). Gastrointest Endosc Clin N Am. 2014 Apr;24(2):169-81. doi: 10.1016/j.giec.2013.11.006. Epub 2014 Jan 25. Review.</citation>
    <PMID>24679229</PMID>
  </reference>
  <reference>
    <citation>Meng Y, Cao C, Song S, Li Y, Liu S. Endoscopic band ligation versus endoscopic submucosal dissection and laparoscopic resection for small gastric stromal tumors. Surg Endosc. 2016 Jul;30(7):2873-8. doi: 10.1007/s00464-015-4571-5. Epub 2015 Oct 21.</citation>
    <PMID>26490768</PMID>
  </reference>
  <reference>
    <citation>Bang CS, Baik GH, Shin IS, Suk KT, Yoon JH, Kim DJ. Endoscopic submucosal dissection of gastric subepithelial tumors: a systematic review and meta-analysis. Korean J Intern Med. 2016 Sep;31(5):860-71. doi: 10.3904/kjim.2015.093. Epub 2016 Feb 22. Review.</citation>
    <PMID>26898597</PMID>
  </reference>
  <reference>
    <citation>Cho JW; Korean ESD Study Group. Current Guidelines in the Management of Upper Gastrointestinal Subepithelial Tumors. Clin Endosc. 2016 May;49(3):235-40. doi: 10.5946/ce.2015.096. Epub 2016 Feb 22. Review.</citation>
    <PMID>26898512</PMID>
  </reference>
  <reference>
    <citation>Zhang Q, Li Y, Meng Y, Bai Y, Cai JQ, Han ZL, Wang Z, Zhi FC, Liu SD. Should the Integrity of Mucosa Be Considered in Endoscopic Resection of Gastric Submucosal Tumors? Gastroenterology. 2016 Apr;150(4):822-4.e9. doi: 10.1053/j.gastro.2016.01.040. Epub 2016 Feb 11.</citation>
    <PMID>26874075</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2017</study_first_submitted>
  <study_first_submitted_qc>March 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2017</study_first_posted>
  <last_update_submitted>May 14, 2017</last_update_submitted>
  <last_update_submitted_qc>May 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GIST</keyword>
  <keyword>ESD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

